AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first ...

AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

AbbVie (ABBV) said it has received FDA approval for the combination antibiotic treatment Emblaveo, which was co-developed ...

NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the ...

AbbVie (NYSE:ABBV) said it has received FDA approval for its intravenous antibiotic treatment Emblaveo. The FDA approved Emblaveo, a combination of aztreonam and avibactam, for use in combination with ...

AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

Because of this alteration of the metronidazole molecule, a concentration gradient is created and maintained which promotes the drug’s intracellular transport. The reduced form of metronidazole ...

Because of this alteration of the metronidazole molecule, a concentration gradient is created and maintained which promotes the drug’s intracellular transport. The reduced form of metronidazole ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

Metronidazole is added if anaerobic activity ... be redosed if the bariatric surgery exceeds two half-lives of the drug from the time the first dose was administered or if the operation exceeds ...